The addition of a second anti HER2 monoclonal antibody, pertuzumab [11] and antibody–drug conjugates like T-DM1 and trastuzumab deruxtecan further improve outcomes in HER2+ breast cancer [12, 13]. Here, ERBB2 is linked to breast cancer.